33
Participants
Start Date
June 30, 2014
Primary Completion Date
August 31, 2014
Study Completion Date
August 31, 2014
Single-hormone closed-loop strategy
Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
Dual-hormone closed-loop strategy
Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) and Glucagon (Eli Lilly and Company) will be used.
Insulin pump therapy
Subjects will use conventional pump therapy to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
Institut de recherches cliniques de Montréal, Montreal
Montreal Children's Hospital of the MUHC
OTHER
Institut de Recherches Cliniques de Montreal
OTHER